Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	100.02	99.92	331.55	36.27	54
Short-Term Investments	826.23	534.22	27.23	234.08	230.15
Cash & Short-Term Investments	926.25	634.13	358.77	270.35	284.15
Cash Growth	46.07%	76.75%	32.71%	-4.86%	-35.28%
Accounts Receivable	53.82	-	-	-	-
Receivables	53.82	-	-	-	-
Inventory	34.07	-	-	-	-
Prepaid Expenses	13.79	3.15	2.6	1.34	1.01
Restricted Cash	5	-	-	-	-
Total Current Assets	1,033	637.28	361.37	271.68	285.16
Property, Plant & Equipment	4.59	3.27	1.2	1.65	1.83
Other Intangible Assets	4.73	-	-	-	-
Total Assets	1,042	640.55	362.57	273.33	287
Accounts Payable	43.6	28.04	23.83	21.38	1.02
Accrued Expenses	124.7	89.98	91.46	55.05	45.22
Current Portion of Leases	0.98	0.53	0.6	0.41	0.32
Total Current Liabilities	169.28	118.55	115.89	76.84	46.56
Long-Term Debt	117.57	115.48	49.29	-	-
Long-Term Leases	1.02	1.19	-	0.39	0.47
Total Liabilities	287.86	235.21	165.18	77.23	47.03
Common Stock	0	0	0	0	0
Additional Paid-In Capital	2,556	1,741	1,160	863.5	665.39
Retained Earnings	-1,802	-1,336	-962.66	-667.31	-425.46
Comprehensive Income & Other	0.47	0.47	-0.03	-0.08	0.05
Shareholders' Equity	754.38	405.33	197.39	196.11	239.97
Total Liabilities & Equity	1,042	640.55	362.57	273.33	287
Total Debt	119.57	117.19	49.89	0.8	0.79
Net Cash (Debt)	806.68	516.94	308.88	269.55	283.36
Net Cash Growth	56.05%	67.36%	14.59%	-4.88%	-35.36%
Net Cash Per Share	37.92	27.66	18.02	16.30	18.34
Filing Date Shares Outstanding	22.08	19.9	18.14	17.1	16.02
Total Common Shares Outstanding	22	19.88	18.1	17.1	15.51
Working Capital	863.65	518.73	245.48	194.85	238.61
Book Value Per Share	34.28	20.39	10.90	11.47	15.47
Tangible Book Value	749.65	405.33	197.39	196.11	239.97
Tangible Book Value Per Share	34.07	20.39	10.90	11.47	15.47

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q